文献速递新发突发、热带与寄生虫病

新型登革热既往感染即时检测用于疫苗接种前筛查的评估

Evaluation of a new point-of-care test to determine prior dengue infection for potential use in pre-vaccination screening.
PubMed 文献 · Clin Microbiol Infect · 2020-08-28

该研究在菲律宾宿务大规模登革热疫苗接种前采集的儿童血清样本中,评估了一种自动化登革热IgG荧光免疫分析法的性能。以中和试验为参考,该检测在1000名儿童中总体特异性为90.7%(95%CI: 82.5-95.9%),敏感性为91.8%(95%CI: 89.8-93.5%),但对单一血清型登革热感染史的敏感性降至51.2%(95%CI: 42.3-61.0%),提示其当前状态不足以用于疫苗接种前筛查。

要点

  • 该登革热IgG荧光免疫分析法的敏感性和特异性未达到理想的95%和98%标准。
  • 对既往单一血清型登革热感染,该检测敏感性仅51.2%,漏检风险高。
  • 该检测操作简便、适合即时检测,但需进一步优化和验证性能。

核心结论

  • 该检测当前性能不足以用于登革热疫苗接种前筛查,尤其对既往单一血清型感染检测敏感性低。

研究设计与样本

  • 研究使用菲律宾宿务大规模登革热疫苗接种前采集的儿童血清样本,纳入1000名儿童(平均年龄10.56岁,54.4%女性),评估ichroma™ II登革热荧光免疫分析法,以中和试验为参考标准。

主要发现

  • 1000名儿童中,中和试验显示86/1000(8.6%)血清阴性,914/1000(91.4%)血清阳性。
  • 该检测总体特异性为90.7%(95%CI: 82.5-95.9%),敏感性为91.8%(95%CI: 89.8-93.5%)。
  • 对单一血清型登革热感染史亚组,敏感性降至51.2%(95%CI: 42.3-61.0%)。

临床怎么用

  • 该检测目前不宜直接用于疫苗接种前筛查,需改进性能后再评估其应用价值。

局限性

  • 原文未明确报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Vaccination with the first licensed dengue vaccine is recommended only for those who have had previous infection with dengue virus (DENV). A point-of-care test with the desired sensitivity of 95% and specificity of 98% could facilitate pre-vaccination screening. We evaluated a newly developed, automated dengue immunoglobulin fluorescence immunoassay for determining dengue serostatus. METHODS: We used serum samples collected just prior to a mass dengue vaccination in Cebu, Philippines. Healthy children residing in Bogo and Balamban who would be 9-14 years old at the time of the mass dengue vaccination were eligible to participate. We evaluated the ichroma™ II dengue fluorescence immunoassay (Boditech Med Incorporated, Gang-won-do, Republic of Korea) using a neutralization test (NT) as the reference assay. RESULTS: We enrolled 2996 children (mean age 10.39 years, 51.7% female) in the cohort and included a subsample of 1000 (mean age 10.56 years, 54.4% female) in this study. Of the 1000 children, 86/1000 (8.6%) tested seronegative and 914/1000 (91.4%) seropositive for DENV antibodies by neutralization testing. Compared with the NT, the dengue IgG fluorescence immunoassay had an overall specificity of 90.7% (95%CI: 82.5-95.9%) and a sensitivity of 91.8% (95%CI: 89.8-93.5%) for determining dengue seropositivity. The sensitivity declined to 51.2% (42.3-61.0%) for the detection of the subset with a monotypic dengue profile. CONCLUSION: The insufficient specificity and sensitivity (particularly in the detection of a previous monotypic dengue infection) would render the test, in its current state, inadequate for pre-vaccination screening. Considering its user-friendly interphase and possibility of point-of-care use, the test could be further developed and validated to improve its performance characteristics.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Daag JV, Ylade M, Adams C, et al. Evaluation of a new point-of-care test to determine prior dengue infection for potential use in pre-vaccination screening. Clin Microbiol Infect. 2020. PMID: 32866651. doi:10.1016/j.cmi.2020.08.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。